Jump to content

Recommended Posts

Posted

http://today.reuters.com/news/articlein ... URGENT.XML

Jan 10 (Reuters) - Cell Therapeutics Inc. (CTIC.O: Quote, Profile , Research) (CTIC.MI: Quote, Profile , Research) said it filed for a special protocol assessment with the U.S. Food and Drug Administration for the design of its late-stage trial of Xyotax for women with advanced lung cancer.

The trial will focus exclusively on women with normal estrogen levels, the subset where Xyotax demonstrated the greatest survival advantage, the company said in a statement. (Reporting by Shikhar Balwani in Bangalore)

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.